Literature DB >> 32581656

Software simulation of tumour motion dose effects during flattened and unflattened ITV-based VMAT lung SBRT.

Marta Adamczyk1, Marta Kruszyna-Mochalska1,2, Anna Rucińska3, Tomasz Piotrowski1,2.   

Abstract

PURPOSE: Restricted studies comparing different dose rate parameters are available while ITV-based VMAT lung SBRT planning leads to perform the analysis of the most suitable parameters of the external beams used. The special emphasis was placed on the impact of dose rate on dose distribution variations in target volumes due to interplay effects.
METHODS: Four VMAT plans were calculated for 15 lung tumours using 6 MV photon beam quality (flattening filter FF vs. flattening filter free FFF beams) and maximum dose rate of 600 MU/min, 1000 MU/min and 1400 MU/min. Three kinds of motion simulations were performed finally giving 180 plans with perturbed dose distributions.
RESULTS: 6FFF-1400 MUs/min plans were characterized by the shortest beam on time (1.8 ± 0.2 min). Analysing the performed motion simulation results, the mean dose (Dmean) is not a sensitive parameter to related interplay effects. Looking for local maximum and local minimum doses, some discrepancies were found, but their significance was presented for individual patients, not for the whole cohort. The same was observed for other verified dose metrics.
CONCLUSIONS: Generally, the evaluation of VMAT robustness between FF and FFF concepts against interplay effect showed a negligible effect of simulated motion influence on tumour coverage among different photon beam quality parameters. Due to the lack of FFF beams, smaller radiotherapy centres are able to perform ITV-based VMAT lung SBRT treatment in a safe way. Radiotherapy department having FFF beams could perform safe, fast and efficient ITV-based VMAT lung SBRT without a concern about significance of interplay effects.
© 2020 Greater Poland Cancer Centre. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  FFF; Lung; Moving targets; Radiotherapy; Stereotactic body radiation therapy

Year:  2020        PMID: 32581656      PMCID: PMC7300152          DOI: 10.1016/j.rpor.2020.06.003

Source DB:  PubMed          Journal:  Rep Pract Oncol Radiother        ISSN: 1507-1367


  33 in total

1.  Frameless high dose rate stereotactic lung radiotherapy: intrafraction tumor position and delivery time.

Authors:  Nicolas Peguret; Max Dahele; Johan P Cuijpers; Ben J Slotman; Wilko F A R Verbakel
Journal:  Radiother Oncol       Date:  2013-05-23       Impact factor: 6.280

Review 2.  SBRT targets that move with respiration.

Authors:  Sonja Dieterich; Olga Green; Jeremy Booth
Journal:  Phys Med       Date:  2018-11-17       Impact factor: 2.685

Review 3.  Geometrical and dosimetrical uncertainties in hypofractionated radiotherapy of the lung: A review.

Authors:  Marco Schwarz; Giovanni Mauro Cattaneo; Livia Marrazzo
Journal:  Phys Med       Date:  2017-02-24       Impact factor: 2.685

4.  4DCT-based evaluation of lung tumour motion during the breathing cycle.

Authors:  M Adamczyk; M Konkol; M Matecka-Nowak; T Piotrowski
Journal:  Neoplasma       Date:  2019-12-17       Impact factor: 2.575

5.  Under-reported dosimetry errors due to interplay effects during VMAT dose delivery in extreme hypofractionated stereotactic radiotherapy.

Authors:  Tobias Gauer; Thilo Sothmann; Oliver Blanck; Cordula Petersen; René Werner
Journal:  Strahlenther Onkol       Date:  2018-02-15       Impact factor: 3.621

6.  Stereotactic ablative radiation therapy versus conventionally fractionated radiation therapy for stage I small cell lung cancer.

Authors:  Vivek Verma; Shaakir Hasan; Rodney E Wegner; Stephen Abel; Athanasios Colonias
Journal:  Radiother Oncol       Date:  2018-12-31       Impact factor: 6.280

7.  MLC tracking for lung SABR reduces planning target volumes and dose to organs at risk.

Authors:  Vincent Caillet; Paul J Keall; Emma Colvill; Nicholas Hardcastle; Ricky O'Brien; Kathryn Szymura; Jeremy T Booth
Journal:  Radiother Oncol       Date:  2017-06-24       Impact factor: 6.280

8.  Stereotactic body radiation therapy versus conventionally fractionated radiation therapy for early stage non-small cell lung cancer.

Authors:  Waqar Haque; Vivek Verma; Praveen Polamraju; Andrew Farach; E Brian Butler; Bin S Teh
Journal:  Radiother Oncol       Date:  2018-07-18       Impact factor: 6.280

9.  Time dependence of intrafraction patient motion assessed by repeat stereoscopic imaging.

Authors:  Mischa S Hoogeman; Joost J Nuyttens; Peter C Levendag; Ben J M Heijmen
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-11-08       Impact factor: 7.038

10.  Local control rates in stereotactic body radiotherapy (SBRT) of lung metastases associated with the biologically effective dose.

Authors:  Daniel Zucca Aparicio; Ovidio Hernando Requejo; Miguel Ángel de la Casa de Julián; Carmen Rubio Rodríguez; Pedro Fernández Letón
Journal:  Rep Pract Oncol Radiother       Date:  2019-01-22
View more
  4 in total

1.  Dosimetric study of Hounsfield number correction effect in areas influenced by contrast product in lungs case.

Authors:  Yassine Oulhouq; Dikra Bakari; Deae-Eddine Krim; Mustapha Zerfaoui; Abdeslem Rrhioua; Soufiane Berhili; Loubna Mezouar
Journal:  Rep Pract Oncol Radiother       Date:  2021-08-12

2.  Impact of Dosimetric Parameters on Interplay Effects in 6 MV Flattening Filter-Free Photon Beams to Treat Lung Cancer.

Authors:  Vanida Poolnapol; Taweap Sanghangthum; Mintra Keawsamur
Journal:  J Med Phys       Date:  2022-03-31

3.  Dose delivery accuracy on helical tomotherapy for 4-dimensional tumor motion - a phantom study.

Authors:  Raghavendra Holla; David Khanna; V K Sathiya Narayanan
Journal:  Rep Pract Oncol Radiother       Date:  2021-06-09

4.  Forecasting of the composite dose for organs at risk and solid targets with random movements during different image-guided scenarios of the photon radiation therapy. Solution for the Varian therapeutic line.

Authors:  Adam Ryczkowski; Tomasz Piotrowski
Journal:  Rep Pract Oncol Radiother       Date:  2021-06-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.